PII "ost-west Express" Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: PII "ost-west Express" Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

PII "ost-west Express" — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

PII "ost-west Express"

Pharmaceutical Importer · Poland · Advanced Oncology Focus · $1.1M Total Trade · DGFT Verified

PII "ost-west Express" is a pharmaceutical importer based in Poland with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 21 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. PII "ost-west Express" sources from 2 verified Indian suppliers, with Reliance Life Sciences Private Limited accounting for 82.8% of imports.

PII "ost-west Express" — Import Portfolio & Supplier Network

PII "ost-west Express" import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to PII "ost-west Express"?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Reliance Life Sciences Private Limited	$447.5K	11	82.8%
Naprod Life Sciences Private Limited	$93.0K	7	17.2%

PII "ost-west Express" sources from across .

What Formulations Does PII "ost-west Express" Import?

Formulation	Value	Ships
Pemetrexed 500MG: pemetrexed for	$293.0K	7
Diaprazole-omeprazole for injection 40MG	$77.7K	4
Bortirel 3.5 MG :mozetrox	$54.5K	2
Bortirel 3.5 MG: mozetrox	$50.0K	1
Bortirel 1 MG: mozetrox, lyophilisate	$50.0K	1
Despazole esomeprazole sodium for	$13.7K	1
Omeprazole for injection 40MG (omeprazole for injection 40MG)(2000 vials)	$1.0K	1
Despazole (esomeprazole sodium for injection 40MG)(1000 vials)	$600	1

PII "ost-west Express" imports 8 distinct pharmaceutical formulations. Showing top 8 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Pemetrexed	Advanced Oncology	$550.0K	11	1.2%	10
2	Trastuzumab	Advanced Oncology	$500.0K	10	0.6%	5

PII "ost-west Express" imports 2 pharmaceutical products across 1 categories into Poland totaling $1.1M.

PII "ost-west Express" — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

PII "ost-west Express" is a pharmaceutical importer based in Poland, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a range of oncology medications to meet the therapeutic needs of the Polish market. While specific details about its parent company and exact headquarters location are not publicly disclosed, PII "ost-west Express" plays a significant role in Poland's pharmaceutical distribution network, particularly in the oncology segment.

2Distribution Network

The distribution network of PII "ost-west Express" encompasses strategic partnerships with Indian pharmaceutical manufacturers, notably Reliance Life Sciences Private Limited and Naprod Life Sciences Private Limited. These collaborations facilitate the importation of critical oncology medications, including Pemetrexed and Trastuzumab, into Poland. The company's logistics capabilities are tailored to handle the complexities of pharmaceutical imports, ensuring compliance with both Polish and European Union regulations. While specific warehouse locations and geographic coverage details are not publicly available, PII "ost-west Express" is integral to the supply chain, ensuring the availability of essential oncology treatments across Poland.

3Industry Role

PII "ost-west Express" functions primarily as a pharmaceutical importer, focusing on sourcing finished formulations from India to supply the Polish market. Its role is pivotal in bridging the gap between Indian pharmaceutical manufacturers and Polish healthcare providers, particularly in the oncology sector. By importing specialized medications like Pemetrexed and Trastuzumab, the company contributes to the diversification and availability of cancer treatments in Poland, thereby enhancing patient access to essential therapies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — PII "ost-west Express"

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

PII "ost-west Express" demonstrates a high degree of sourcing concentration, with 100% of its imported products originating from two Indian suppliers: Reliance Life Sciences Private Limited and Naprod Life Sciences Private Limited. This focused sourcing strategy indicates a strategic choice to establish strong, reliable partnerships with key manufacturers. The stability of these relationships is evidenced by the consistent importation of specific oncology medications, such as Pemetrexed and Trastuzumab, over multiple shipments. However, this concentration also presents potential risks, including supply chain disruptions or regulatory changes affecting these suppliers. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of PII "ost-west Express"'s supply chain is closely tied to the stability and reliability of its Indian suppliers. The company's focus on a limited number of suppliers suggests a deep integration and trust in these partnerships. However, this reliance also means that any disruptions—such as production issues, regulatory changes, or geopolitical events in India—could significantly impact the company's ability to supply essential oncology medications to the Polish market. To bolster supply chain resilience, PII "ost-west Express" might consider developing relationships with additional suppliers and diversifying its product portfolio to reduce dependency on a narrow supplier base.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Pharmaceutical Law Act, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics to be marketed in Poland, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA), ensuring compliance with EU standards for safety, efficacy, and quality.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Poland stipulate that all imported medicines must have a valid marketing authorization issued by the URPL. Manufacturers and importers must adhere to Good Manufacturing Practice (GMP) standards recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, wholesale distribution authorization is required for entities involved in the distribution of medicinal products, ensuring compliance with storage, handling, and transportation regulations to maintain product integrity.

Quality & Labeling

PII "ost-west Express" — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

PII "ost-west Express" focuses on importing oncology medications, specifically Pemetrexed and Trastuzumab, indicating a strategic emphasis on addressing the therapeutic needs of cancer patients in Poland. The market demand for these products is driven by the increasing prevalence of cancer and the need for effective treatments. By sourcing these medications from India, PII "ost-west Express" aims to provide cost-effective alternatives to existing therapies, thereby enhancing patient access to essential cancer treatments.

2Sourcing Profile

PII "ost-west Express" employs a sourcing strategy centered on high-quality generic drugs, particularly in the oncology category. The company's preference for finished pharmaceutical formulations aligns with its goal of ensuring product quality and regulatory compliance. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a suitable partner for sourcing these formulations. This strategy enables PII "ost-west Express" to offer competitive pricing and reliable supply to the Polish market.

3Market Positioning

Seller's Guide — How to Become a Supplier to PII "ost-west Express"

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with PII "ost-west Express," particularly those offering high-quality oncology medications that meet EU GMP standards. Gaps in the company's current sourcing include potential diversification of suppliers and expansion into additional therapeutic areas. Indian exporters can position themselves as alternative suppliers by demonstrating product quality, regulatory compliance, and the ability to meet the specific needs of the Polish market.

2Requirements & Qualifications

Indian exporters aiming to supply PII "ost-west Express" and the Polish market must obtain marketing authorization from the URPL and ensure compliance with EU GMP standards. Products must undergo batch testing and meet stability requirements. Labeling must be in Polish and include all necessary information. Additionally, exporters must adhere to serialization mandates to enhance product traceability and prevent counterfeiting.

3How to Approach

Frequently Asked Questions — PII "ost-west Express"

What products does PII "ost-west Express" import from India?

PII "ost-west Express" imports 2 pharmaceutical products across 1 categories. Top imports: Pemetrexed ($550.0K), Trastuzumab ($500.0K).

Who supplies pharmaceuticals to PII "ost-west Express" from India?

PII "ost-west Express" sources from 2 verified Indian suppliers. The primary supplier is Reliance Life Sciences Private Limited (82.8% of imports, $447.5K).

What is PII "ost-west Express"'s total pharmaceutical import value?

PII "ost-west Express"'s total pharmaceutical import value from India is $1.1M, based on 21 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does PII "ost-west Express" focus on?

PII "ost-west Express" imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full PII "ost-west Express" Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.